Malaria in Southern United States

QUESTION:

Why is there not a prevalence of malaria in the southern United States when we are bitten almost daily by the “little beasts?”

ANSWER:

Malaria once was relatively common in the southern United States. Transmission used to be possible due to the favorable climatic conditions for the development both of the mosquito as well as the malaria parasite. Huge advances in the control and treatment of malaria were made directly as a result of increased interest in the disease after the US occupation of Cuba and the building of the Panama Canal in the early years of the 20th century. This vastly reduced the number of cases of the disease, but the final, concerted effort to eradicate malaria came in the 1940s.

This was due to a federal public health program called the National Malaria Eradication Program (NMEP), and as a result of its actions, malaria transmission was halted throughout the United States by 1951. The program was launched in 1947, coordinated by the newly formed Communicable Disease Center (now the Center for Disease Control and Prevention, or CDC) and mostly involved reducing the number of mosquitoes in and around people’s homes. This was done through the wide-spread spraying of DDT—during the years of NMEP, it has been estimated that more than 6.5 million homes were sprayed with the insecticide. Alongside spraying, mosquito breeding habitats were also removed, through wetland drainage, and human monitoring and treatment efforts were stepped up. By 1949, malaria was no longer considered a disease of public health importance, and it was declared eradicated from the United States in 1951.

Having said that, the species of mosquito that transmit malaria still exist in the USA, and particularly in the southern states, which means that there is always a risk of small, localized outbreaks of the disease, particularly during hot and wet seasons.

Climate change may also increase the zones where malaria is at risk of being able to develop within the United States. For this reason, the CDC continually monitors the small number of cases reported each year in the USA (there were about 1500 cases in 2007—all but four of these cases, however, were the result of travelers to malarial areas outside of the USA bringing the disease back with them) to ensure that they are prepared and well-informed should an outbreak arise.

A Research Agenda for Malaria Eradication: Vaccines

Abstract: Vaccines could be a crucial component of efforts to eradicate malaria. Current attempts to develop malaria vaccines are primarily focused on Plasmodium falciparum and are directed towards reducing morbidity and mortality. Continued support for these efforts is essential, but if malaria vaccines are to be used as part of a repertoire of tools for elimination or eradication of malaria, they will need to have an impact on malaria transmission.

We introduce the concept of “vaccines that interrupt malaria transmission” (VIMT), which includes not only “classical” transmission-blocking vaccines that target the sexual and mosquito stages but also pre-erythrocytic and asexual stage vaccines that have an effect on transmission. VIMT may also include vaccines that target the vector to disrupt parasite development in the mosquito. Importantly, if eradication is to be achieved, malaria vaccine development efforts will need to target other malaria parasite species, especially Plasmodium vivax, where novel therapeutic vaccines against hypnozoites or preventive vaccines with effect against multiple stages could have enormous impact. A target product profile (TPP) for VIMT is proposed and a research agenda to address current knowledge gaps and develop tools necessary for design and development of VIMT is presented.

Citation: The malERA Consultative Group on Vaccines (2011) A Research Agenda for Malaria Eradication: Vaccines. PLoS Med 8(1): e1000398. doi:10.1371/journal.pmed.1000398
Published: January 25, 2011

Funding: malERA received a grant from the Bill & Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: No competing interests: PLA, CC, VM, AS, DW. GB is the Chair of MALVAC, Chair of the USAID Malaria Vaccine Development Program Scientific Consultants Group, a member of the Board of Roll Back Malaria, and the APMEN Advisory Board. RB is an employee of Glaxo SmithKline (GSK) and owns GSK stock. GSK is developing malaria vaccines. At the time of the malERA meetings, RB was employed by the Bill & Melinda Gates Foundation. CL states that the PATH Malaria Vaccine Initiative has partnerships with several commercial entities developing malaria vaccines. Each partnership has defined access conditions.

Abbreviations: TBV, transmission-blocking vaccine; TPP, target product profile; VIMT, vaccines that interrupt malaria transmission

Copyright: © 2011 The malERA Consultative Group on Vaccines. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

More information:
A Research Agenda for Malaria Eradication: Vaccines (PDF)